436 related articles for article (PubMed ID: 35931636)
1. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
Chen H; Huang Z; Chang S; Hu M; Lu Q; Zhang Y; Wang H; Xiao Y; Wang H; Ge Y; Zou Y; Cui F; Han S; Zhang M; Wang S; Zhu X; Zhang B; Li Z; Ren J; Chen X; Ma R; Zhang L; Guo X; Luo L; Sun X; Yang X
Vaccine; 2022 Aug; 40(36):5322-5332. PubMed ID: 35931636
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.
Shenyu W; Xiaoqian D; Bo C; Xuan D; Zeng W; Hangjie Z; Qianhui Z; Zhenzhen L; Chuanfu Y; Juan Y; Gang Z; Huakun L
Vaccine; 2022 Aug; 40(36):5356-5365. PubMed ID: 35933275
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.
Huang X; Fan T; Li L; Nian X; Zhang J; Gao X; Zhao W; Chen W; Zhang Z; Yao Z; Han X; Shi J; Wang Y; Bian H; Shi N; Li X; Duan K; Li G; Yang X
Hum Vaccin Immunother; 2022 Nov; 18(5):2079924. PubMed ID: 35714276
[TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.
Fan R; Huang X; Nian X; Ou Z; Zhou J; Zhang J; Zeng P; Zhao W; Deng J; Chen W; Chen S; Duan K; Chen Y; Li X; Zhang J; Yang X
Hum Vaccin Immunother; 2022 Dec; 18(1):1-9. PubMed ID: 34473607
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
[TBL] [Abstract][Full Text] [Related]
13. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China.
Chen Y; Xiao Y; Ye Y; Jiang F; He H; Luo L; Chen H; Shi L; Mu Q; Chen W; Guo X; Zhang M; Li J; Guan Q; Chen Z; Yang X
Front Immunol; 2022; 13():1080408. PubMed ID: 36569946
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
Shinde V; Cho I; Plested JS; Agrawal S; Fiske J; Cai R; Zhou H; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou B; Lewis M; Price-Abbott P; Patel N; Massare MJ; Smith G; Keech C; Fries L; Glenn GM
Lancet Infect Dis; 2022 Jan; 22(1):73-84. PubMed ID: 34563277
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
Chu K; Xu K; Tang R; Tian X; Hu J; Yang T; Li C; Hu Y; Zeng G
Vaccine; 2020 Aug; 38(37):5940-5946. PubMed ID: 32732142
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
